Published in Blood on January 27, 2005
Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol (2012) 3.52
The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol Cell Biol (2011) 3.01
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood (2010) 2.71
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood (2007) 2.58
PHD fingers in human diseases: disorders arising from misinterpreting epigenetic marks. Mutat Res (2008) 2.31
Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol (2007) 2.14
New strategies in the treatment of multiple myeloma. Clin Cancer Res (2013) 2.05
Function of alternative splicing. Gene (2012) 2.00
Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol Cell Biol (2008) 1.96
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood (2010) 1.82
The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood (2007) 1.60
Genome-wide transcriptional analysis of the human cell cycle identifies genes differentially regulated in normal and cancer cells. Proc Natl Acad Sci U S A (2008) 1.53
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene (2007) 1.49
The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. Blood (2015) 1.47
Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress. J Clin Invest (2012) 1.21
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica (2008) 1.20
A glue for heterochromatin maintenance: stable SUV39H1 binding to heterochromatin is reinforced by the SET domain. J Cell Biol (2005) 1.10
Role for the nuclear receptor-binding SET domain protein 1 (NSD1) methyltransferase in coordinating lysine 36 methylation at histone 3 with RNA polymerase II function. Proc Natl Acad Sci U S A (2010) 1.09
The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene (2012) 1.07
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J (2012) 0.97
Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene (2012) 0.95
Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. Leukemia (2007) 0.92
The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition. J Biol Chem (2012) 0.89
An open and shut case for the role of NSD proteins as oncogenes. Transcription (2011) 0.86
Microfluidic chips for detecting the t(4;14) translocation and monitoring disease during treatment using reverse transcriptase-polymerase chain reaction analysis of IgH-MMSET hybrid transcripts. J Mol Diagn (2007) 0.85
Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination. Clin Cancer Res (2014) 0.84
Identification of a novel proliferation-related protein, WHSC1 4a, in human gliomas. Neuro Oncol (2008) 0.83
Dysregulation of protein methyltransferases in human cancer: An emerging target class for anticancer therapy. Cancer Sci (2016) 0.82
Histone methyltransferases: novel targets for tumor and developmental defects. Am J Transl Res (2015) 0.82
Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma. Oncotarget (2013) 0.81
MMSET is dynamically regulated during cell-cycle progression and promotes normal DNA replication. Cell Cycle (2016) 0.81
Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol (2016) 0.81
MMSET: role and therapeutic opportunities in multiple myeloma. Biomed Res Int (2014) 0.80
MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib. Leukemia (2015) 0.80
Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention. Curr Opin Oncol (2015) 0.79
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res (2015) 0.78
H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer. Adv Cancer Res (2016) 0.78
MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis. Haematologica (2015) 0.77
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). Oncotarget (2016) 0.77
A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex. PLoS One (2014) 0.77
Partners in crime: The role of tandem modules in gene transcription. Protein Sci (2015) 0.76
AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis. J Clin Invest (2017) 0.75
Dynamic behavior of the post-SET loop region of NSD1: Implications for histone binding and drug development. Protein Sci (2016) 0.75
MB4-2/MB4-3 transcripts of IGH-MMSET fusion gene in t(4;14)(pos) multiple myeloma indicate poor prognosis. Oncotarget (2017) 0.75
SMART, a simple modular architecture research tool: identification of signaling domains. Proc Natl Acad Sci U S A (1998) 36.83
SMART 4.0: towards genomic data integration. Nucleic Acids Res (2004) 19.37
Studying protein dynamics in living cells. Nat Rev Mol Cell Biol (2001) 8.43
Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol (2004) 6.55
Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene (2001) 4.70
Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood (2003) 4.67
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood (1998) 3.69
Rapid exchange of histone H1.1 on chromatin in living human cells. Nature (2000) 3.59
Measurement of dynamic protein binding to chromatin in vivo, using photobleaching microscopy. Methods Enzymol (2004) 3.02
Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet (2002) 2.96
Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem Sci (2002) 2.80
WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet (1998) 2.77
Nucleolar components involved in ribosome biogenesis cycle between the nucleolus and nucleoplasm in interphase cells. J Cell Biol (2001) 2.70
Chromosome translocations in multiple myeloma. Oncogene (2001) 2.61
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood (2002) 2.38
The PWWP domain of Dnmt3a and Dnmt3b is required for directing DNA methylation to the major satellite repeats at pericentric heterochromatin. Mol Cell Biol (2004) 2.30
Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat (1999) 2.24
The PWWP domain of mammalian DNA methyltransferase Dnmt3b defines a new family of DNA-binding folds. Nat Struct Biol (2002) 2.24
The PWWP domain: a potential protein-protein interaction domain in nuclear proteins influencing differentiation? FEBS Lett (2000) 2.24
Chromatin targeting of de novo DNA methyltransferases by the PWWP domain. J Biol Chem (2004) 2.02
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood (2002) 1.87
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood (2001) 1.84
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood (2004) 1.82
Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia (2004) 1.71
A transcript map of the newly defined 165 kb Wolf-Hirschhorn syndrome critical region. Hum Mol Genet (1997) 1.71
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood (2002) 1.65
t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients. Br J Haematol (2003) 1.49
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood (2004) 1.49
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol (2004) 1.45
Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res (2000) 1.28
Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol (2004) 1.20
A unique mRNA initiated within a middle intron of WHSC1/MMSET encodes a DNA binding protein that suppresses human IL-5 transcription. Am J Respir Cell Mol Biol (2001) 1.17
Comparative analysis of a novel gene from the Wolf-Hirschhorn/Pitt-Rogers-Danks syndrome critical region. Genomics (1999) 1.15
Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma. Br J Haematol (2004) 1.13
The role of the MLL gene in infant leukemia. Int J Hematol (2003) 1.04
Establishment of a new human myeloma cell line, KMS-18, having t(4;14)(p16.3;q32.3) derived from a case phenotypically transformed from Ig A-lambda to BJP-lambda, and associated with hyperammonemia. Int J Oncol (1998) 1.02
Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood (2003) 0.97
A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res (2004) 0.97
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br J Haematol (2001) 0.97
A molecular study of the t(4;14) in multiple myeloma. Br J Haematol (2002) 0.95
The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood (1997) 0.93
Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. Haematologica (2002) 0.82
Translocation t(11;14) in multiple myeloma: Analysis of translocation breakpoints on der(11) and der(14) chromosomes suggests complex molecular mechanisms of recombination. Genes Chromosomes Cancer (2004) 0.80
Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism. Oncogene (2003) 0.78
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
PARP inhibition: PARP1 and beyond. Nat Rev Cancer (2010) 6.70
Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol (2008) 5.87
Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer (2002) 5.30
Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell (2002) 5.19
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 4.33
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab (2008) 4.08
Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol (2013) 3.72
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood (2011) 3.58
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell (2004) 3.55
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature (2011) 3.10
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res (2009) 3.06
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 2.98
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell (2008) 2.84
Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Res (2008) 2.70
PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J Biol Chem (2007) 2.62
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood (2007) 2.58
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell (2007) 2.56
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood (2002) 2.38
RNF8- and RNF168-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites. EMBO J (2012) 2.34
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc (2007) 2.34
A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood (2008) 2.25
Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest (2012) 2.24
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res (2007) 2.19
Using FRAP and mathematical modeling to determine the in vivo kinetics of nuclear proteins. Methods (2003) 2.15
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
ATM-dependent DNA damage-independent mitotic phosphorylation of H2AX in normally growing mammalian cells. Mol Biol Cell (2005) 2.13
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood (2009) 2.12
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood (2012) 2.07
Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr (2008) 2.01
Catalytic function of the PR-Set7 histone H4 lysine 20 monomethyltransferase is essential for mitotic entry and genomic stability. J Biol Chem (2008) 1.99
Nucleoplasmic beta-actin exists in a dynamic equilibrium between low-mobility polymeric species and rapidly diffusing populations. J Cell Biol (2006) 1.98
Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood (2010) 1.96
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood (2012) 1.88
A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood (2005) 1.87
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood (2009) 1.86
Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J Biol Chem (2007) 1.80
Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res (2007) 1.78
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol (2010) 1.77
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol (2007) 1.76
Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr (2010) 1.76
A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol (2011) 1.74
BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair. J Cell Biol (2010) 1.74
H1 family histones in the nucleus. Control of binding and localization by the C-terminal domain. J Biol Chem (2005) 1.59
Approach to the treatment of multiple myeloma: a clash of philosophies. Blood (2011) 1.57
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res (2009) 1.57
Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ (2009) 1.57
Prognostic factors in multiple myeloma: it's in the genes. Clin Cancer Res (2003) 1.55
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res (2003) 1.51
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood (2004) 1.49
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk (2012) 1.48
Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol (2009) 1.45
Mechanotransduction from the ECM to the genome: are the pieces now in place? J Cell Biochem (2008) 1.45
Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood (2009) 1.44
The differential mobilization of histones H3.1 and H3.3 by herpes simplex virus 1 relates histone dynamics to the assembly of viral chromatin. PLoS Pathog (2013) 1.42
Effects of presurgical exercise training on cardiorespiratory fitness among patients undergoing thoracic surgery for malignant lung lesions. Cancer (2007) 1.41
Actin dynamics and functions in the interphase nucleus: moving toward an understanding of nuclear polymeric actin. Biochem Cell Biol (2009) 1.38
RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell (2003) 1.35
The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives. Curr Opin Cell Biol (2006) 1.35
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc (2010) 1.34
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc (2010) 1.32
Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord (2005) 1.30
Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. Trends Mol Med (2005) 1.29
Quantitative analysis of CBP- and P300-induced histone acetylations in vivo using native chromatin. Mol Cell Biol (2003) 1.29
IMWG consensus on maintenance therapy in multiple myeloma. Blood (2012) 1.29
PARP activation regulates the RNA-binding protein NONO in the DNA damage response to DNA double-strand breaks. Nucleic Acids Res (2012) 1.28
Differential regulation of IL-12 and IL-10 gene expression in macrophages by the basic leucine zipper transcription factor c-Maf fibrosarcoma. J Immunol (2002) 1.27
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol (2012) 1.27